Highest-materiality recent filing
Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).
Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M
Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.
Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY
Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).
Adaptive Biotechnologies subsidiary Digital Biotechnologies closes Series A up to $15M
Digital Biotechnologies, 70%-owned subsidiary, held initial closing of Series A Preferred Stock financing.
Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised
Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.
Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025
Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.
Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance
Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.
Adaptive Biotechnologies shareholders elect Chad Robins and approve say-on-pay, auditor
Chad Robins elected Class III director with 80.95% of votes cast; 12.8M broker non-votes.
Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance
Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.
Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M
Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).
Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M
Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).
Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance
Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).
Shareholders elect directors with majority support; Nasdaq confirms audit committee compliance
Peter Neupert elected with 69.15% for (30.85% withhold); Michelle Griffin with 82.93% for.
Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M
Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).
Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024
Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.
Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named
Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.
CFO Tycho Peterson resigns; Kyle Piskel named CFO effective April 8
Tycho Peterson resigned as CFO effective April 5, 2024; resignation voluntary with no disagreement.
Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M
Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.
As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.
Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.
On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the “ Company ”) Tycho Peterson submitted his resignation.
Max materiality 0.80 · Median 0.70 · Most common event earnings